Table 1. Immunogenicity profile of intradermal vaccines in healthy volunteers <65 y.
| Authors |
No. of subjects (intradermal) |
Age range |
Study year |
Intradermal antigen dose |
Immunogenicity (CHMP criteria) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seroprotection rate (%) | Seroconversion rate (%) | GMT ratio | |||||||||||
| |
|
|
|
|
H1N1 |
H3N2 |
B |
H1N1 |
H3N2 |
B |
H1N1 |
H3N2 |
B |
| Belshe |
123 (60) |
18–60 y |
2001–02 |
6 µg |
100.0 |
100.0 |
100.0 |
31.7 |
35.0 |
25.0 |
4.0 |
4.0 |
2.4 |
| Leroux-Roels |
766 (382) |
18–57 y |
2005–06 |
9 µg |
92.4 |
99.7 |
90.6 |
74.3 |
85.1 |
76.4 |
16.2 |
28.2 |
12.1 |
| Beran |
762 (382) |
18–57 y |
2003–04 |
3 µg |
72.7 |
88.5 |
28.5 |
53.1 |
35.4 |
21.0 |
7.32 |
3.48 |
2.38 |
| |
761 (381) |
18–57 y |
2003–04 |
6 µg |
71.3 |
88.2 |
32.9 |
55.1 |
43.0 |
27.3 |
8.38 |
4.19 |
2.73 |
| |
1086 (541) |
19–58 y |
2004–05 |
9 µg |
90.0 |
97.2 |
73.0 |
43.0 |
53.1 |
63.4 |
4.3 |
4.4 |
7.8 |
| |
826 (417) |
20–59 y |
2005–06 |
9 µg |
90.7 |
100.0 |
83.3 |
14.8 |
60.2 |
24.1 |
2.0 |
4.6 |
2.3 |
| Arnou |
1744 (1308) |
18–60 y |
2006 |
9 µg |
87.2 |
93.5 |
72.9 |
57.5 |
66.5 |
56.7 |
9.17 |
11.5 |
6.39 |
| Frenck Jr |
1591 (399) |
18–64 y |
2005–06 |
6 µg |
76.5 |
99.7 |
75.0 |
- |
- |
- |
3.62 |
3.59 |
4.78 |
| 1591 (394) | 18–64 y | 2005–06 | 9 µg | 81.0 | 99.5 | 76.2 | - | - | - | 3.92 | 4.03 | 5.59 | |